SAN DIEGO, Sept. 17 /PRNewswire-FirstCall/ -- Pharmatek -- a pharmaceutical chemistry development organization supporting the pharmaceutical industry -- today announced the opening of its highly-potent and cytotoxic facility located in San Diego.
The 18,000 sq. ft. facility includes newly constructed analytical and formulation development laboratories and cGMP manufacturing suites dedicated to the development of highly-potent and cytotoxic drug product for early phase clinical trials.
“Highly-potent and cytotoxic compounds are among the most sensitive drugs to handle and produce,” said Kevin Rosenthal, director of manufacturing of Pharmatek. “Our primary goal when designing the facility was to optimize product quality while ensuring operator safety to guarantee our clients’ drug candidates move smoothly from discovery to clinical trials.”
The facility holds a State of California Food and Drug Branch (FDB) Drug Manufacturers License and is currently working on a number of highly-potent development projects. The FDB license authorizes Pharmatek to manufacture and ship clinical material from its state-of-the-art highly-potent and cytotoxic manufacturing and development site.
“The highly-potent facility is a significant addition to our service offering,” said Timothy Scott, president of Pharmatek. “We are always looking for ways to better meet our client’s drug development outsourcing needs, and the highly-potent and cytotoxic facility strengthens our ability to provide a broader level of services to our clients.”
About Pharmatek Laboratories, Inc.
Pharmatek Laboratories Inc. is a premier pharmaceutical chemistry development company providing full-service pharmaceutical chemistry product development for the pharmaceutical industry. Pharmatek focuses on bringing client compounds from discovery to the clinic with services that include compound selection, analytical development, preformulation testing, formulation development, GMP manufacturing, stability storage and testing, and highly-potent and cytotoxic drug development.
Statements contained in this media release which are not historical facts may
constitute forward-looking statements. All forward-looking statements are subject to risks and uncertainties which could cause actual results to differ
from those projected including sales forecasts and strategic expansion. The
trademarks Pharmatek, Pharmatek Laboratories, Inc., Hot Rod Chemistry and
Pharmatek Formulation Screening are all property of Pharmatek Laboratories,
Inc. Additional information about Pharmatek Laboratories may be obtained at
CONTACT: Elizabeth Hickman, Marketing Manager of Pharmatek Laboratories,
Inc., +1-858-805-6383, ext. 235, ehickman@pharmatek.com
Web site: http://www.pharmatek.com/
